Atsena Gene Therapy Restored Vision in Trial Patients
Results from an 18-month clinical study showed improved visual acuity in patients with X-linked retinoschisis.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Should medical research prioritize funding gene therapies for rare vision loss conditions?
Atsena Therapeutics has released 18-month follow-up data for its gene therapy ATSN-201, which targets X-linked retinoschisis. The study reported that seven out of nine treated eyes experienced foveal schisis closure and improved visual acuity.
Why it matters
This research addresses X-linked retinoschisis, an inherited condition that leads to progressive blindness for which there are currently no approved gene therapies. The findings suggest a potential pathway for restoring central retinal function in patients facing long-term vision loss.
The therapy uses an AAV.SPR capsid, a modified virus designed to spread laterally through retinal tissue to target photoreceptors. Seven of nine treated eyes achieved at least 7 dB of improvement in microperimetry, a test measuring retinal sensitivity, after 18 months.
The players
Atsena Therapeutics
A biotechnology company based in Durham, N.C., focusing on gene therapies for inherited retinal diseases using proprietary viral capsids.
American Academy of Optometry
A professional association that hosts scientific meetings for the dissemination of clinical research in vision science.
The details
ATSN-201 is administered via subretinal injection, a procedure involving the delivery of therapeutic material directly beneath the retina. The AAV.SPR capsid functions as the delivery vehicle, ensuring the genetic payload reaches the central retina's photoreceptors, the specialized cells that convert light into nerve signals. By addressing the structural failure of the fovea, the central portion of the retina responsible for sharp vision, the therapy targets the source of the vision loss.
Timeline
September 30 - October 3, 2026: Atsena Therapeutics presented the findings at the American Academy of Optometry Annual Meeting.
June 2026: Dosing for the pivotal Part C cohort began.
Q1 2027: Atsena expects to complete enrollment for the Part C cohort.
1H 2028: Topline results for the Part C cohort are anticipated.
2H 2028: Atsena plans to file a BLA with regulatory authorities.
The Tech Race
This development represents a competitive move in the effort to refine viral vector delivery for retinal cells. It marks a push to improve upon standard AAV delivery methods that have historically struggled to reach sufficient photoreceptor populations in the central retina.
This gene therapy is currently in clinical trials and is not yet available for patient use. The potential impact depends on the successful completion of the ongoing Part C trial and subsequent regulatory approval for those living with X-linked retinoschisis.
The takeaway
This trial shows that targeted viral delivery can restore structural and functional vision in patients with inherited retinal disease. Observers should track the Part C topline results in 2028, which will serve as the primary indicator for the therapy's path toward regulatory approval.
What happens next
Atsena Therapeutics aims to conclude enrollment for the pivotal Part C trial by the end of Q1 2027, with topline results expected in the first half of 2028.
Further reading
For more on the latest research in this sector, visit the Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Should medical research prioritize funding gene therapies for rare vision loss conditions?
